BACKGROUND Infection with Angiostrongylus vasorum may cause severe clinical disease, even death in dogs, however, due to the often non-specific clinical signs, diagnosis is not always straightforward. Regular prophylactic treatment may offer a safe means to protect dogs against infection. The efficacy of a novel oral endectocide containing moxidectin, sarolaner and pyrantel was investigated for the prevention of angiostrongylosis in dogs in three placebo-controlled, randomized, masked studies. The initial study (Study 1) determined the efficacious dosage of moxidectin in the combination product by evaluating three different dose levels, and two follow-up studies (Studies 2 and 3) confirmed the efficacy of the selected moxidectin dose. METHODS Animals were infected orally with 200 infective third-stage larvae (L3) of A. vasorum and were treated 28 days later with the combination product or with placebo. Timing of dosing relative to infection allowed for efficacy to be evaluated against the immature adult (L5) stage. Dogs in Study 1 received treatments with oral tablets to deliver 3, 12 or 24 µg/kg moxidectin in combination with 2 mg/kg sarolaner and 5.0 mg/kg pyrantel (as pamoate salt) or placebo. In Studies 2 and 3, Simparica Trio™ tablets were administered to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel (as pamoate salt). Efficacy of the combination product was calculated as the percent reduction in adult worm counts at necropsy relative to placebo. RESULTS In Study 1, the 3, 12 and 24 µg/kg moxidectin dosage in the combination product provided 7.2%, 54.5% and 94.7% efficacy against the immature adult stages of A. vasorum, respectively. Studies 2 and 3 confirmed that the efficacy of 24 µg/kg moxidectin combined with 1.2 mg/kg sarolaner and 5 mg/kg pyrantel in Simparica Trio™ was ≥ 92.9%. All three studies established that a single oral administration of 24 µg/kg moxidectin in the combination product provided effective prophylactic treatment for angiostrongylosis, reduced L1 production and fecal excretion and minimized the tissue damage to the lungs. CONCLUSIONS A single oral treatment of dogs with Simparica Trio™ providing moxidectin at a minimum dose of 24 µg/kg was efficacious in the prevention of angiostrongylosis.

中文翻译：

---

口服莫昔克丁，sarolaner和吡喃酮（Simparica Trio™）的组合预防狗实验性血管圆管血管感染的功效。

背景技术血管圆管血管炎的感染可能导致严重的临床疾病，甚至在犬中死亡，但是，由于通常是非特异性的临床体征，诊断并不总是那么简单。定期的预防性治疗可能提供一种保护狗免受感染的安全方法。在三项安慰剂对照，随机，掩盖研究中，研究了一种包含莫昔克丁，沙拉那钠和吡喃酮的新型口服内毒素对狗血管性毛细血管病的预防作用。最初的研究（研究1）通过评估三种不同的剂量水平确定了复方产品中莫西菌素的有效剂量，两项后续研究（研究2和3）证实了所选莫西菌素剂量的疗效。方法用200只感染性第三阶段A的幼虫（L3）经口感染动物。血管，并在28天后用联合产品或安慰剂治疗。相对于感染的给药时间允许针对未成熟的成年人（L5）阶段评估疗效。研究1中的狗接受了口服片剂治疗，以分别提供3、12或24 µg / kg莫昔克丁与2 mg / kg sarolaner和5.0 mg / kg吡喃（如棕榈酸盐）或安慰剂。在研究2和3中，使用Simparica Trio™片剂提供的最低剂量为1.2 mg / kg sarolaner，24 µg / kg莫昔克丁和5.0 mg / kg吡咯烷（作为棕榈酸盐）。组合产品的功效计算为尸检时相对于安慰剂减少的成虫蠕虫计数的百分比。结果在研究1中，组合产品中3、12和24 µg / kg莫西菌素的剂量提供了针对未成年A期的7.2％，54.5％和94.7％的功效。血管，分别。研究2和3证实，在Simparica Trio™中将24 µg / kg莫西菌素与1.2 mg / kg的sarolaner和5 mg / kg的吡喃酮联合使用的效率≥92.9％。所有这三项研究都确定，在联合产品中单次口服24 µg / kg莫昔克丁可以为血管性毛细血管病提供有效的预防性治疗，减少L1的产生和粪便排泄，并将对肺的组织损伤降至最低。结论用Simparica Trio™犬提供的莫昔克丁最低剂量为24 µg / kg进行单次口服治疗，可有效预防血管狭窄。所有这三项研究都确定，在联合产品中单次口服24 µg / kg莫昔克丁可以为血管性毛细血管病提供有效的预防性治疗，减少L1的产生和粪便排泄，并将对肺的组织损伤降至最低。结论用Simparica Trio™犬提供的莫昔克丁最低剂量为24 µg / kg进行单次口服治疗，可有效预防血管狭窄。所有这三项研究都确定，在联合产品中单次口服24 µg / kg莫昔克丁可以为血管性毛细血管病提供有效的预防性治疗，减少L1的产生和粪便排泄，并将对肺的组织损伤降至最低。结论用Simparica Trio™犬提供的莫昔克丁最低剂量为24 µg / kg进行单次口服治疗，可有效预防血管狭窄。